Details
Stereochemistry | ACHIRAL |
Molecular Formula | C31H33N3O6S |
Molecular Weight | 575.675 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC4CCCC4)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C5=C(C)C=CC=C5
InChI
InChIKey=YEEZWCHGZNKEEK-UHFFFAOYSA-N
InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)
Molecular Formula | C31H33N3O6S |
Molecular Weight | 575.675 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:43:31 UTC 2023
by
admin
on
Sat Dec 16 17:43:31 UTC 2023
|
Record UNII |
XZ629S5L50
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175777
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
||
|
NDF-RT |
N0000000083
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
||
|
NCI_THESAURUS |
C29712
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
||
|
LIVERTOX |
NBK547915
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
||
|
WHO-ATC |
R03DC01
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
||
|
WHO-VATC |
QR03DC01
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000091929
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
107753-78-6
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
GG-93
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
m11576
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | Merck Index | ||
|
7244
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
XZ629S5L50
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
SUB00128MIG
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
CHEMBL603
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
C47785
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
5717
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
3322
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
DB00549
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
DTXSID5023746
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
Zafirlukast
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
ZAFIRLUKAST
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
2855
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
C062735
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
114970
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | RxNorm | ||
|
XZ629S5L50
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
10100
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | |||
|
N0000185504
Created by
admin on Sat Dec 16 17:43:32 UTC 2023 , Edited by admin on Sat Dec 16 17:43:32 UTC 2023
|
PRIMARY | Cytochrome P450 2C9 Inhibitors [MoA] |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> INHIBITOR |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> INHIBITOR |
in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations.
|
||
|
METABOLIC ENZYME -> INHIBITOR |
in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Route of Elimination | PHARMACOKINETIC |
|
||||
Volume of Distribution | PHARMACOKINETIC |
|
||||
Cmax | PHARMACOKINETIC |
|
Populations PHARMACOKINETIC |
|
||
Route of Elimination | PHARMACOKINETIC |
|
||||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Cmax | PHARMACOKINETIC |
|
Populations PHARMACOKINETIC |
|
||
Tmax | PHARMACOKINETIC |
|
||||
Onset of Action | PHARMACOKINETIC |
|
|
|||